Multicenter, Open Label, Phase 3 Trial of ATA129 for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)

What is the purpose of this trial?

This is a multicenter, open-label, single-arm phase 3 trial to assess the efficacy and safety of ATA129 for the treatment of Epstein Barr Virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of solid organ transplant (SOT) after failure of rituximab or rituximab plus chemotherapy.


Gender: Both


Atara Biotherapeutics

Start Date: 03/12/2018

End Date: 11/30/2020

Last Updated: 06/24/2018

Study HIC#: 2000021894

Get Involved

For more information about this study, contact:
Ricarda Tomlin
+1 203-785-2073
ricarda.tomlin@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image